Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet…
Partner Content
-
-
Leading CDMO to attend CPHI Milan 2026 in Italy
Globally renowned contract development and manufacturing organisation (CDMO) Piramal Pharma Solutions (PPS) will showcase its expertise at the upcoming CPHI…
-
Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Few areas of pharmaceutical manufacturing have attracted as much investment in recent years as high-potency containment. The expansion of oncology…
-
Oral solid dose at a turning point: Scaling for the next generation of therapies
As the first oral GLP-1 receptor agonists launch in 2026, we are reminded yet again of the enduring importance of…
-
How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies…
-
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
When a warning letter from the U.S. Food and Drug Administration (FDA) lands on a quality leader's desk, the instinct…
-
What drives time-to-randomization in oncology trials?
In the United States, an estimated 2,041,910 new cases of cancer were diagnosed in 2025, with 618,120 people dying from…
-
How DFE Pharma supports confident continuous manufacturing decisions
For pharmaceutical manufacturers, the question is whether a specific formulation can perform consistently under continuous conditions. That requires evidence on…
-
The rare disease revolution: The state of play for CGTs in orphan diseases
Rare diseases are chronic conditions that affect between 3.5% and 5.9% of the global population. About 80% of rare diseases…
-
Develop site-centric protocols to optimize enrollment and maximize performance
In an attempt to meet regulatory expectations, clinical trials are challenged by highly complex protocol design. But these study plans…